Empagliflozin May Reduce Cardiovascular Mortality in T2D With LVH

For patients with T2D and left ventricular hypertrophy, empagliflozin reduced the risk for cardiovascular death vs placebo.

Source link

Related posts

Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.


Sex Differences in Percutaneous Coronary Intervention—Insights From the Coronary Angiography and PCI Registry of the German Society of Cardiology [Coronary Heart Disease]


Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet TherapeuticsHighlights [Translational Sciences]


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy